retatrutide maximum dose clinical trials Reta trial data & dosing — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 for metabolic health — targeting GLP-1, GIP I get this question pretty

Second, several experiments whether they involve slices of brain tissue, animals, and even human volunteers have strongly suggested that GLP-1 drugs specifically act on our dopamine cycles and affect neural activity in the hypothalamus, the appetite-controlling region of the brain

If the 4 mg maintenance arm proves non-inferior for weight maintenance in Phase 3, researchers may be able to titrate up to a high working dose during the active weight-loss phase, then step back down to a lower 4 mg maintenance dose for the long stabilization phase

Comprehensive medical evaluation and aggressive nutritional support are particularly important in this age group

GLP-1 RAs have also been found to reduce the risk of acute and chronic kidney disease, cardiovascular events, liver disease, sepsis, and substance use disorders